Meeting
2017 Gastrointestinal Cancers Symposium
Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.
Authors
Jonathan M. Loree
The University of Texas MD Anderson Cancer Center, Houston, TX
Jonathan M. Loree , Aaron Sha , Maryam Soleimani , Maria Yi Ho , Hagen F. Kennecke , Winson Y. Cheung , Karen E. Mulder , Shirin Abadi , Jennifer L. Spratlin , Sharlene Gill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 710)
DOI
10.1200/JCO.2017.35.4_suppl.710
Abstract #
710
Poster Bd #
J20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.
First Author: Romain Cohen
Poster
2020 Gastrointestinal Cancers Symposium
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis.
First Author: Suganija Lakkunarajah
Poster
2012 ASCO Annual Meeting
Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials.
First Author: Christopher Twelves
Poster
2023 ASCO Quality Care Symposium
Impact of the IDEA collaboration study on practice patterns of adjuvant chemotherapy in patients with stage III colon cancer: A population-based study.
First Author: Sunil Samnani